OrbiMed’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $312M | Hold |
7,959,538
| – | – | 6.8% | 2 |
|
|
2025
Q4 | $123M | Hold |
7,959,538
| – | – | 2.51% | 11 |
|
|
2025
Q3 | $163M | Hold |
7,959,538
| – | – | 3.91% | 5 |
|
|
2025
Q2 | $160M | Hold |
7,959,538
| – | – | 4.02% | 5 |
|
|
2025
Q1 | $157M | Hold |
7,959,538
| – | – | 3.76% | 5 |
|
|
2024
Q4 | $179M | Hold |
7,959,538
| – | – | 3.72% | 6 |
|
|
2024
Q3 | $203M | Hold |
7,959,538
| – | – | 3.72% | 6 |
|
|
2024
Q2 | $186M | Sell |
7,959,538
-1,038,800
| -12% | -$21.9M | 3.7% | 7 |
|
|
2024
Q1 | $158M | Hold |
8,998,338
| – | – | 2.91% | 9 |
|
|
2023
Q4 | $125M | Hold |
8,998,338
| – | – | 2.49% | 9 |
|
|
2023
Q3 | $123M | Hold |
8,998,338
| – | – | 2.64% | 7 |
|
|
2023
Q2 | $184M | Buy |
8,998,338
+2,125
| +0% | +$42.9K | 3.35% | 3 |
|
|
2023
Q1 | $197M | Buy |
8,996,213
+7,899,571
| +720% | +$161M | 3.9% | 2 |
|
|
2022
Q4 | $17.9M | Hold |
1,096,642
| – | – | 0.34% | 67 |
|
|
2022
Q3 | $10K | Hold |
1,096,642
| – | – | 0.19% | 85 |
|
|
2022
Q2 | $5.35K | Hold |
1,096,642
| – | – | 0.1% | 110 |
|
|
2022
Q1 | $8.25M | Hold |
1,096,642
| – | – | 0.13% | 105 |
|
|
2021
Q4 | $9.87M | Hold |
1,096,642
| – | – | 0.13% | 117 |
|
|
2021
Q3 | $17.9M | Buy |
1,096,642
+416,666
| +61% | +$8.66M | 0.2% | 103 |
|
|
2021
Q2 | $21.5M | Hold |
679,976
| – | – | 0.22% | 96 |
|
|
2021
Q1 | $23M | Hold |
679,976
| – | – | 0.22% | 91 |
|
|
2020
Q4 | $60M | Hold |
679,976
| – | – | 0.53% | 53 |
|
|
2020
Q3 | $55.3M | Hold |
679,976
| – | – | 0.7% | 42 |
|
|
2020
Q2 | $75.2M | Hold |
679,976
| – | – | 1.06% | 30 |
|
|
2020
Q1 | $43.6M | Buy |
+679,976
| New | +$43.3M | 0.74% | 43 |
|
Other funds holding ELVN
PCH
CC
VPC
BG
VCM
FFM
VA